Capricor Therapeutics (GB:0HTB)
LSE:0HTB

Capricor Therapeutics (0HTB) Share Price & Analysis

0 Followers

Financials

Annual

0HTB FAQ

What was Capricor Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Capricor Therapeutics’s market cap?
Currently, no data Available
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is Nov 09, 2023 which is in 42 days.
    How were Capricor Therapeutics’s earnings last quarter?
    Capricor Therapeutics released its earnings results on Aug 07, 2023. The company reported -€0.274 earnings per share for the quarter, beating the consensus estimate of -€0.331 by €0.057.
      Is Capricor Therapeutics overvalued?
      According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Capricor Therapeutics pay dividends?
        Capricor Therapeutics does not currently pay dividends.
        What is Capricor Therapeutics’s EPS estimate?
        Capricor Therapeutics’s EPS estimate is -€0.32.
          How many shares outstanding does Capricor Therapeutics have?
          Capricor Therapeutics has 25,776,867 shares outstanding.
            What happened to Capricor Therapeutics’s price movement after its last earnings report?
            Capricor Therapeutics reported an EPS of -€0.274 in its last earnings report, beating expectations of -€0.331. Following the earnings report the stock price went same N/A.
              Which hedge fund is a major shareholder of Capricor Therapeutics?
              Among the largest hedge funds holding Capricor Therapeutics’s share is Oracle Investment Management Inc. It holds Capricor Therapeutics’s shares valued at N/A.

                ---

                Capricor Therapeutics Stock Smart Score

                5
                Neutral
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10
                The Capricor Therapeutics Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Capricor Therapeutics

                Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.

                ---

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                Capricor Therapeutics
                Fate Therapeutics
                Rocket Pharmaceuticals
                Bluebird Bio

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis